DOCSLIB.ORG

SCODE Generic Measurement Formulation Expiry Date Stock

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SCODE Generic Measurement Formulation Expiry Date Stock Stock Available with Stock POSITnew SCODE Generic Measurement Formulation Expiry Date Stock Available Annual Consumption Stock Position Months / AC A001 ACETAZOLAMIDE 250MG TABLET 01/07/2025 155,160 268,170 6.9 A003 ACETYLSALICYLIC ACID 300MG TABLET 31/03/2023 728 4,228 2.1 A004 ACETYLSALICYLIC ACID 300MG TABLET DISPERSIBLE 31/08/2021 4,608 8,320 6.6 A005 ACITRETIN 25MG CAPSULE 30/04/2021 10,680 24,600 5.2 A006 ALLOPURINOL 100MG TABLET 15/09/2023 974,950 1,690,900 6.9 A007 ALFACALCIDOL 0.25µ CAPSULE 30/11/2021 269,730 566,580 5.7 A008 ALFACALCIDOL 1µ CAPSULE 31/05/2022 28,890 114,330 3.0 A009 AMANTADINE HYDROCHLORIDE 100MG TABLET/CAPSULE 31/01/2025 22,980 63,446 4.3 A010 CO-AMILOZIDE 5MG|50MG TABLET 01/11/2024 200,940 374,746 6.4 A011 AMIODARONE HYDROCHLORIDE 200MG TABLET 31/12/2021 142,128 472,752 3.6 A012 AMITRIPTYLINE HYDROCHLORIDE 10MG TABLET 30/04/2023 51,772 648,368 1.0 A013 AMITRIPTYLINE HYDROCHLORIDE 25MG TABLET 22/06/2022 702,550 1,290,150 6.5 A014 CO-AMOXICLAV 250MG|125MG TABLET 01/08/2022 72,180 231,926 3.7 A017 ANTACID CHEWABLE TABLETS TABLET CHEWABLE 30/11/2022 64,800 306,950 2.5 A018A ASCORBIC ACID 100MG TABLETS 31/05/2023 27,000 175,000 1.9 A019 ATENOLOL 100MG TABLET 01/07/2025 1,072,020 2,395,320 5.4 A020A ATROPINE SULFATE 500MCG TABLET 31/01/2023 300 20,050 0.2 A021 AZATHIOPRINE 50MG TABLET 01/09/2025 240,200 664,236 4.3 A022 BACLOFEN 10MG TABLET 01/01/2025 191,900 420,650 5.5 A024 BENDROFLUAZIDE 5MG TABLET 30/11/2021 1,180,928 2,343,404 6.0 A025 TRIHEXYPHENIDYL HYDROCHLORIDE 2MG TABLET 01/02/2025 387,900 828,040 5.6 A027 BISACODYL 5MG TABLET GASTRO-RES 30/09/2022 33,600 53,860 7.5 A030 BROMOCRIPTINE MESYLATE 2.5MG TABLET 31/01/2025 17,010 68,790 3.0 A032 BUMETANIDE 1MG TABLET 01/04/2025 3,815,900 8,065,400 5.7 A033 BUMETANIDE 5MG TABLET 31/05/2021 18,116 40,712 5.3 A034 BUSULFAN 2MG TABLET 31/03/2022 775 700 13.3 A038 CALCIUM LACTATE 300MG TABLET 28/02/2025 501,500 899,500 6.7 A039 CAPTOPRIL 25MG TABLET 01/10/2023 9,000 27,780 3.9 A041 CARBAMAZEPINE [TEGRETOL] 200MG TABLET 30/09/2021 0 1,067,400 0.0 A042 CARBIDOPA|LEVODOPA 10MG|100MG TABLET 31/08/2025 523,500 1,331,700 4.7 A044 CARBIMAZOLE 5MG TABLET 01/11/2023 28,100 99,900 3.4 A045 CEPHALEXIN 250MG TABLET/CAPSULE 30/09/2022 1,428 5,928 2.9 A046 CHLORAMBUCIL 2MG TABLET 31/01/2022 3,325 775 51.5 A049 CHLOROQUINE PHOSPHATE 250MG TABLET 30/04/2022 20 80 3.0 A052 CHLORPROMAZINE HYDROCHLORIDE 25MG TABLET 01/09/2025 14,600 548,170 0.3 A053 CHLORPROMAZINE HYDROCHLORIDE 100MG TABLET 01/06/2025 45,350 121,908 4.5 A058 CLINDAMYCIN 150MG TABLET/CAPSULE 31/08/2021 20,496 96,168 2.6 A059 CLOFAZIMINE 100MG TABLET 31/12/2022 0 0 A061 CLOMIPRAMINE HYDROCHLORIDE 10MG TABLET 31/01/2022 152,012 326,116 5.6 A062 CLOMIPRAMINE HYDROCHLORIDE 25MG TABLET 01/04/2025 628,500 1,280,500 5.9 A063 COLCHICINE 500µ TABLET 30/11/2022 91,000 269,400 4.1 A065 CO-TRIMOXAZOLE 480MG TABLET 30/09/2025 53,120 103,680 6.1 A066 CYCLIZINE HYDROCHLORIDE 50MG TABLET 30/06/2022 15,800 47,900 4.0 A067 CYCLOPHOSPHAMIDE 50MG TABLET 31/10/2023 10,800 18,900 6.9 A070 CYPROTERONE ACETATE 50MG TABLET 31/08/2023 0 30,240 0.0 A072 DANTROLENE SODIUM 25MG CAPSULE 28/02/2023 2,100 9,500 2.7 A073 DAPSONE 50MG TABLET 28/02/2023 3,248 18,368 2.1 A074 DAPSONE 100MG TABLET 30/11/2021 1,736 9,548 2.2 A075 DEXAMETHASONE 0.5MG TABLET 01/06/2025 17,000 46,000 4.4 A076 DICLOFENAC SODIUM 25MG TABLET GASTRO-RES 01/03/2024 257,520 634,368 4.9 A077 DIGOXIN 0.0625MG TABLET 30/09/2022 491,932 874,720 6.7 A078 DIGOXIN 0.25MG TABLET 31/03/2022 50,456 115,724 5.2 A079 DILTIAZEM HYDROCHLORIDE 60MG TABLET 01/04/2025 68,650 145,450 5.7 A081 DIPYRIDAMOLE 25MG TABLET 01/10/2024 645,600 1,299,500 6.0 A082 DIPYRIDAMOLE 100MG TABLET 30/06/2024 1,080,000 2,490,432 5.2 A083 DISOPYRAMIDE 100MG CAPSULE 31/01/2023 14,600 27,272 6.4 A085 DISULFIRAM 200MG TABLET 31/05/2023 4,150 15,540 3.2 A089 DYDROGESTERONE 10MG TABLET 30/11/2024 1,008 1,890 6.4 A090 ENALAPRIL MALEATE 5MG TABLET 01/04/2023 2,299,200 4,553,600 6.1 A091 ENALAPRIL MALEATE 20MG TABLET 08/06/2023 1,194,200 2,645,814 5.4 A093 ERYTHROMYCIN 250MG TABLET/CAPSULE 31/03/2023 9,408 23,184 4.9 A094 ETHAMBUTOL HYDROCHLORIDE 400MG TABLET 31/10/2021 9,912 36,456 3.3 A097 ETHOSUXIMIDE 250MG CAPSULE 30/04/2022 4,300 23,100 2.2 A102 FERROUS FUMARATE PROVIDING 65-70MG OF IRON TABLET 30/04/2021 0 121,080 0.0 A102A FERROUS SULPHATE PROVIDING IRON 65-70MG TABLET 31/03/2023 4,600 505,900 0.1 A103 BEZAFIBRATE 400MG TABLET MR 31/08/2024 186,690 346,560 6.5 A104 FLECAINIDE ACETATE 100MG TABLET 31/08/2022 0 177,640 0.0 A105 FLUCLOXACILLIN 250MG CAPSULE 30/04/2022 3,300 70,312 0.6 A106 FLUDROCORTISONE ACETATE 0.1MG TABLET 31/03/2022 720 46,200 0.2 A110 FOLIC ACID 5MG TABLET 31/01/2022 564,444 1,414,468 4.8 A112 FRUSEMIDE 40MG TABLET 30/09/2024 199,420 376,980 6.3 A113 FUSIDATE SODIUM 250MG TABLET 30/11/2021 1,400 1,200 14.0 A114 GLIBENCLAMIDE 5MG TABLET 01/07/2025 123,100 344,124 4.3 A115 GLYCERYL TRINITRATE 500µ TABLET 31/05/2022 212,500 271,200 9.4 A118 GRISEOFULVIN 125MG TABLET 01/04/2025 2,960 6,380 5.6 A119 HALOPERIDOL 0.5MG CAPSULE 30/09/2022 172,520 251,860 8.2 A120 HALOPERIDOL 1.5MG TABLET 31/01/2023 32,536 184,912 2.1 A121 HALOPERIDOL 5MG CAPSULE 01/05/2025 151,000 281,000 6.4 A123 HYDRALAZINE HYDROCHLORIDE 25MG TABLET 31/05/2023 301,320 637,200 5.7 A124 HYDROCORTISONE 20MG TABLET 30/06/2024 27,450 78,060 4.2 A125 HYDROXYCHLOROQUINE SULFATE 200MG TABLET 30/11/2021 16,840 271,770 0.7 A126 HYDROXYCARBAMIDE 500MG CAPSULE 31/05/2024 45,000 185,100 2.9 A127 HYDROXYZINE HYDROCHLORIDE 25MG TABLET 31/08/2022 473,868 1,020,896 5.6 A128 HYOSCINE BUTYLBROMIDE 10MG TABLET 31/07/2024 16,016 45,080 4.3 A129 IBUPROFEN 200MG TABLET 31/05/2022 98,208 206,880 5.7 A130 IMIPRAMINE HYDROCHLORIDE 10MG TABLET 31/08/2023 2,604 14,140 2.2 A131 IMIPRAMINE HYDROCHLORIDE 25MG TABLET 30/06/2023 79,912 163,660 5.9 A132 INDOMETACIN 25MG CAPSULE 31/07/2022 6,238 13,888 5.4 A133 IRON & FOLIC ACID 90-105MG|350-1000µ TABLET/CAPSULE 31/01/2023 34,250 68,600 6.0 A135 ISONIAZID 100MG TABLET 30/09/2021 6,784 6,108 13.3 A137 ISOSORBIDE DINITRATE 10MG TABLET 01/06/2024 154,550 328,100 5.7 A140 LABETALOL HYDROCHLORIDE 100MG TABLET 31/12/2022 25,816 69,980 4.4 A141 LABETALOL HYDROCHLORIDE 200MG TABLET 31/08/2022 43,960 83,272 6.3 A144 CO-BENELDOPA 50MG|12.5MG CAPSULE 31/10/2022 9,200 55,300 2.0 A145 CO-BENELDOPA 100MG|25MG CAPSULE 31/03/2023 34,200 81,000 5.1 A146 CO-BENELDOPA 200MG|50MG CAPSULE 30/11/2022 5,000 10,100 5.9 A147 LITHIUM CARBONATE 400MG TABLET MR 31/10/2022 158,300 480,100 4.0 A148 LOMUSTINE 40MG CAPSULE 31/07/2022 400 200 24.0 A149 LOPERAMIDE HYDROCHLORIDE 2MG CAPSULE 28/02/2025 72,000 161,000 5.4 A151 MAPROTILINE HYDROCHLORIDE 25MG TABLET 01/01/2024 2,640 8,950 3.5 A154 MEDROXYPROGESTERONE ACETATE 5MG TABLET 31/10/2024 1,392 6,068 2.8 A155 MEDROXYPROGESTERONE ACETATE 100MG TABLET 30/09/2021 9,800 35,240 3.3 A156 MEFENAMIC ACID 250MG CAPSULE 31/03/2024 36,500 39,300 11.1 A157 MELPHALAN 2MG TABLET 31/05/2021 375 200 22.5 A160 MERCAPTOPURINE 50MG TABLET 31/05/2024 4,400 29,350 1.8 A163 METFORMIN HYDROCHLORIDE 500MG TABLET 31/08/2023 3,155,220 34,171,392 1.1 A165 METHOTREXATE 2.5MG TABLET 01/04/2025 112,300 401,000 3.4 A166 METHOXSALEN 10MG TABLET 21/10/2023 3,000 800 45.0 A168 METHYLDOPA 250MG TABLET 01/05/2025 68,400 184,300 4.5 A169 METOPROLOL TARTRATE 50MG TABLET 31/03/2021 0 0 A170 METOPROLOL TARTRATE 100MG TABLET 31/07/2024 74,900 87,348 10.3 A171 METRONIDAZOLE 200MG TABLET 30/11/2023 164,590 99,010 19.9 A172 MEXILETINE HYDROCHLORIDE 200MG CAPSULE 31/08/2021 0 360 0.0 A173 MIANSERIN HYDROCHLORIDE 10MG TABLET 01/06/2025 73,400 187,540 4.7 A174 MIANSERIN HYDROCHLORIDE 30MG TABLET 01/05/2025 56,380 215,180 3.1 A176 METOCLOPRAMIDE 10MG TABLET 28/02/2022 19,460 105,112 2.2 A179 NAPROXEN 250MG TABLET 01/11/2024 40,000 75,680 6.3 A183 NIFEDIPINE 10MG TABLET/CAPSULE 01/10/2023 32,200 129,000 3.0 A184 NITROFURANTOIN 50MG CAPSULE 31/01/2023 15,360 51,540 3.6 A185 NORETHISTERONE 5MG TABLET 28/02/2025 2,190 17,670 1.5 A188 OESTROGENS CONJUGATED 0.625MG TABLET 31/07/2021 560 6,496 1.0 A190 ORPHENADRINE HYDROCHLORIDE 50MG TABLET 01/02/2024 40,000 124,500 3.9 A198 PARACETAMOL 500MG TABLET 31/03/2024 3,756,500 4,286,600 10.5 A199 PENECILLAMINE 250MG TABLET 30/09/2023 2,464 3,416 8.7 A202 PHENOXYMETHYLPENICILLIN 250MG TABLET 31/01/2022 66,752 200,480 4.0 A204 PHENYTOIN SODIUM [EPANUTIN] 50MG CAPSULE 30/11/2022 8,848 160,132 0.7 A205 PHENYTOIN SODIUM [EPANUTIN] 100MG CAPSULE 31/12/2022 182,952 779,772 2.8 A207 PHENOXYBENZAMINE HYDROCHLORIDE 10MG CAPSULE 30/06/2021 180 480 4.5 A208 PIMOZIDE 4MG TABLET 31/07/2022 4,900 16,700 3.5 A211 PREDNISOLONE 1MG TABLET 31/05/2021 0 76,552 0.0 A212 PREDNISOLONE EC 5MG TABLET GASTRO-RES 28/02/2023 1,200 847,118 0.0 A213 PREDNISOLONE 5MG TABLET 30/04/2025 132,104 242,676 6.5 A214 PRIMAQUINE PHOSPHATE 7.5MG TABLET 31/03/2022 0 312 0.0 A215 PRIMIDONE [SERB LAB] 250MG TABLET 30/11/2024 32,100 49,800 7.7 A217 PROCARBAZINE 50MG CAPSULE 31/08/2021 1,850 700 31.7 A218 PROCHLORPERAZINE MALEATE 5MG TABLET 31/05/2023 53,060 93,958 6.8 A220 PROMETHAZINE HYDROCHLORIDE 10MG TABLET 31/05/2022 20,776 27,384 9.1 A221 PROMETHAZINE HYDROCHLORIDE 25MG TABLET 01/08/2025 32,610 69,480 5.6 A223 PROPRANOLOL HYDROCHLORIDE 10MG TABLET 01/02/2025 236,250 594,000 4.8 A224 PROPRANOLOL HYDROCHLORIDE 40MG TABLET 01/05/2025 200,400 343,544 7.0 A225 PROPYLTHIOURACIL 50MG TABLET 31/01/2022 2,700 17,600 1.8 A227 PYRAZINAMIDE 500MG TABLET 31/05/2023 29,000 51,890 6.7 A228 PYRIDOSTIGMINE BROMIDE 60MG TABLET 31/07/2022 9,200 169,200 0.7 A229 PYRIDOXINE HYDROCHLORIDE 10MG TABLET 31/08/2021 0 51,760 0.0 A230 PYRIDOXINE HYDROCHLORIDE 50MG
Load more

Recommended publications
  • Signal Tower LR Series
    As a global company, we offer our products and support worldwide. The LR Series conforms to international standards. The PATLITE group has built a global sales network to effectively provide goods and services to customers anywhere. Signal Tower LR Series 4-1-3, Kyutaromachi, Chuo-ku, Osaka 541-0056 Japan TEL. +81-6-7711-8953 FAX. +81-6-7711-8961 E-mail: [email protected] 20130 S. Western Ave. Torrance, CA 90501, U.S.A. TEL. +1-310-328-3222 FAX. +1-310-328-2676 E-mail: [email protected] No.2 Leng Kee Road, #05-01 Thye Hong Centre, Singapore 159086 TEL. +65- 6226-1111 FAX. +65-6324-1411 E-mail: [email protected] Room 1102-1103, No.55, Lane 777, Guangzhong Road (West), ZhabeiDistrict, Shanghai, China 200072 TEL. +86-21-6630-8969 FAX. +86-21-6630-8938 E-mail: [email protected] Am Soeldnermoos 8, D-85399 Hallbergmoos, Germany TEL. +49-811-9981-9770-0 FAX. +49-811-9981-9770-90 E-mail: [email protected] To ensure correct use of these products, read the “Instruction Manual” prior to use. Failure to A2603, Daesung, D-POLIS, 606, Seobusaet-gil, Geumcheon-gu, Seoul, 08504, Korea follow all safeguards can result in fire, electric TEL. +82-2-523-6636 FAX. +82-2-861-9919 E-mail: [email protected] shock, or other accidents.Specifications are subject to change without notice. 7F. No. 91, Huayin St, Datong District Taipei, Taiwan R.O.C TEL. +886-2-2555-1611 FAX. +886-2-2555-1621 E-mail: [email protected] Olympia Thai Tower, 15th Floor 444 Ratchadapisek Road Samsennok, Huay Kwang Bangkok 10310, Thailand TEL.
    [Show full text]
  • Floor Debate November 14, 2011
    Transcript Prepared By the Clerk of the Legislature Transcriber's Office Floor Debate November 14, 2011 [LB1 LB4A LB4 LR3 LR4 LR5 LR6 LR7 LR8 LR9 LR11 LR12 LR13 LR14 LR15 LR21] SENATOR GLOOR PRESIDING SENATOR GLOOR: Good afternoon, ladies and gentlemen. Welcome to the George W. Norris Legislative Chamber for the ninth day of the One Hundred Second Legislature, First Special Session. Our chaplain for today is Senator Hansen. Please rise. SENATOR HANSEN: (Prayer offered.) SENATOR GLOOR: Thank you, Senator Hansen. I call to order the ninth day of the One Hundred Second Legislature, First Special Session. Senators, please record your presence. Roll call. Mr. Clerk, please record. CLERK: I have a quorum present, Mr. President. SENATOR GLOOR: Thank you, Mr. Clerk. Do you have any items for the record? CLERK: I do, Mr. President. Your Committee on Government, Military and Veterans Affairs chaired by Senator Avery, to whom was referred LR8 and LR12, instructs me to report the same, those two resolutions, back to the Legislature with a recommendation they be reported for further consideration. That's all that I have, Mr. President. (Legislative Journal page 71.) [LR8 LR12] SENATOR GLOOR: Thank you, Mr. Clerk. We'll proceed to the first agenda item, confirmation reports. CLERK: Mr. President, the Transportation and Telecommunications Committee chaired by Senator Fischer reports on appointments to the State Highway Commission and to the Nebraska Motor Vehicle Industry Licensing Board. (Legislative Journal page 65.) SENATOR GLOOR: Senator Fischer, you're recognized to open on the confirmation report. SENATOR FISCHER: Thank you, Mr. President and members of the body.
    [Show full text]
  • Submarine Rescue Capability and Its Challenges
    X Submarine Rescue Capability and its Challenges 41496_DSTA 4-15#150Q.indd 1 5/6/10 1:08 AM ABSTRACT Providing rescue to the crew of a disabled submarine is of paramount concern to many submarine-operating nations. Various rescue systems are in operation around the world. In 2007, the Republic of Singapore Navy (RSN) acquired a rescue service through a Public–Private Partnership. With a locally based solution to achieve this time-critical mission, the rescue capability of the RSN has been greatly enhanced. Dr Koh Hock Seng Chew Yixin Ng Xinyun 41496_DSTA 4-15#150Q.indd 2 5/6/10 1:08 AM Submarine Rescue Capability and its Challenges 6 “…[The] disaster was to hand Lloyd B. Maness INTRODUCTION a cruel duty. He was nearest the hatch which separated the flooding sections from the On Tuesday 23 May 1939, USS Squalus, the dry area. If he didn’t slam shut that heavy newest fleet-type submarine at that time metal door everybody on board might perish. for the US Navy, was sailing out of the Maness waited until the last possible moment, Portsmouth Navy Yard for her 19th test dive permitting the passage of a few men soaked in the ocean. This was an important trial for by the incoming sea water. Then, as water the submarine before it could be deemed poured through the hatchway… he slammed seaworthy to join the fleet. USS Squalus was shut the door on the fate of those men aft.” required to complete an emergency battle descent – a ‘crash test’ – by dropping to a The Register Guard, 24 May 1964 periscope depth of 50 feet (about 15 metres) within a minute.
    [Show full text]
  • CHEMICALS and COMPANY IDENTIFICATION Chemical Identifier WDR20-V Product Code WDR20V0001 Company Name PENTEL CO., LTD
    WDR20-V, PENTEL CO., LTD., 2, 2019/01/31, 1/4 Safety Data Sheet (SDS) Preparation Date 2014/08/12 Revision Date 2019/01/31 Section 1 - CHEMICALS AND COMPANY IDENTIFICATION Chemical Identifier WDR20-V Product Code WDR20V0001 Company Name PENTEL CO., LTD. Address 7-2,KOAMICHO,NIHONBASHI,CHUO-KU,TOKYO Company Contact QUALITY ASSURANCE DEPARTMENT I Phone Number 03-5695-7210 Fax Number 03-5645-8204 Mail Address [email protected] Emergency Phone Number 03-5695-7210 Recommended Use and ink Restriction on Use Australian Company Pentel Australia Pty Ltd Address Unit 4, 7 - 9 Orion Road, Lane Cove NSW 2066 Phone 1300 88 87 86 Emergency Phone 02 9425 4800 ABN 72 008 457 725 LRN5,LRN7,LR7,LR10,BLN15,BL17,BL27-V Section 2 - HAZARDS IDENTIFICATION GHS Classification Health Hazards Acute toxicity (Inhalation: dust and mist) Category 4 Skin corrosion/irritation Category 2 Serious eye damage/eye irritation Category 1 Specific target organ toxicity (single exposure) Specific target organ toxicity (single exposure) Other hazards than mentioned above are Not GHS Label Elements Symbols Signal Word Danger Hazard Statements H315 Causes skin irritation H318 Causes serious eye damage H332 Harmful if inhaled H335 May cause respiratory irritation H370 Causes damage to blood,kidney,central nervous Precautionary Statements Prevention Precautionary Avoid breathing gas.(P261) Statements Avoid breathing mist, vapours and spray.(P261) Avoid breathing dust and fume.(P261) Use only outdoors or in a well-ventilated area.(P271) Wear protective gloves.(P280) Wear eye protection
    [Show full text]
  • Webb County Accounts Payable Check Register February 2020
    Webb County Accounts Payable Check Register February 2020 Transaction Transaction Departmental Department TransactionType Payee Item Description Itemized Amount Fund Number Date Amount 111th District Court Check 10931 02/04/2020 ERNEST GARZA $500.00 Indigent Defense $500.00 General Fund 10956 02/04/2020 GONZALEZ DRUKER LAW $300.00 Indigent Defense $300.00 General Fund FIRM P.L.L.C 10986 02/04/2020 LAW OFFICE OF JUAN $882.50 Indigent Defense $882.50 General Fund ABRAHAM PAZ, PLLC 10988 02/04/2020 LAW OFFICE OF RUSSELL $500.00 Indigent Defense $500.00 General Fund JORDAN 11090 02/05/2020 LAW OFFICE OF MARC A $600.00 Indigent Defense $300.00 General Fund GONZALEZ PLLC Indigent Defense $300.00 General Fund 11107 02/05/2020 TOSHIBA BUSINESS $81.74 CONTRACT# **** 07/01/19-07/31/19 $81.74 General Fund SOLUTIONS USA 11133 02/05/2020 SAM'S CLUB DIRECT $124.76 coca-cola $22.84 General Fund frito lay classic mix $51.92 General Fund heft supreme 250 count $12.88 General Fund nabisco classic mix 40 packs $11.36 General Fund SPOONS $10.98 General Fund sprite $11.42 General Fund WATER $3.36 General Fund 11214 02/07/2020 TELLEZ LAW PLLC $1,050.00 Indigent Defense $750.00 General Fund Indigent Defense $300.00 General Fund 11367 02/12/2020 TOSHIBA BUSINESS $80.47 Excess Copies Blk/Color for Estudio $80.47 General Fund SOLUTIONS USA 6570CT and Lexmark XN3150 11384 02/13/2020 DEL RIO LAW FIRM PLLC $4,750.00 Indigent Defense $750.00 General Fund Indigent Defense $1,000.00 General Fund Indigent Defense $500.00 General Fund Indigent Defense $500.00 General
    [Show full text]
  • Cool^^Umwr^Dwm Middle East Truce Due Today
    ■ J t i S t F l Z v M _ ~l ...... ............................................................................. Cood mot'fimfj!iugHi^CSwiilliY. Nor. 11, _, : - •• • -------- ---- ^-------- !-------- r— --------— ---- - / '.’ X \ • \V “ 0 ‘" > y ' ^ — Mnaic I alloy's llonU; !Sewspaper 25' 71st yoar, 65th lssuo_ TWIN FALLS, IDAHO Cool^^uMWr^dwm tape,” he said. -Uiis would have to' Pre.sident in not rclenslnu tlie — ny MAWfcYN-EIJ:IOTT-— -fijttiH'dnyr-nighlr -at—Uio-4QtH- — "Rcfgrring trr ; “ thr!r~;litt><~-^ annual Cabaret Internationale saiii'-'l would bo the first one tom e from the President,, ' tapes that Involve WntcrKatc.T TImcB'Ncws Writer problem alxujt Mr. (.'ox ond. iund *raislnR dinner for the to ask for his rfslgnntion." Goldwater siii<l. and if there believf he was wrong In that Mr.- lUchardson," Goldwatcf .Snake River Area Council ,of ‘■rm only one American and w^re some concrete reason to and many things," ho said. • .bURLEY - Sen, Barry Siiid, "Cox’s treatnu*nt of his the Boy Scout.s of America. thore woro over 40 million.who resign he would, in . order to The President was wrong in in brief Goldwater. R-Ariz.. oaked’ tlie responsibility all along was a _^liuiro-iiuno- w uyaiiutU hc__vuledJar-titiSldcnL tlix on.lhc,. save the country-frou) further standing on privilege In regard AHierifanrpeopU^-to-^'plny-it- litllo-lacklng-Ho-wus-tha^only— Senate would ever Impeach ' said. Goldwater said he did not divisiiin. , ‘ In the rtMca^~Qnhc~tnpPF cool’; in their c rits for one who disagreed on- how to ii-ithauL-SQmL-. fjud. - " ■ • f»r' . ■ :•‘I 1'jiuicair.ilailJLalefcnill>)c 'm po ttryim; todefendthe___ bcga^sgbccause "there‘'there is no auchauchthini thing i^Hwiiiaw»yalu>>i»tlal-lM>iiilMul;.
    [Show full text]
  • ORIGINAL Portland General Electric Company \/ 12I SW ..Calnw'astreet • Portland, Oregon 97204 November 12, 2002 ~ ~Ro ,,*R
    Jnofflclal FERC-Generated PDF of 20021115-0446 Received by FERC OSEC 11/12/2002 in Docket#: P-477-024 ORIGINAL Portland General Electric Company \/ 12I SW ..Calnw'aStreet • Portland, Oregon 97204 November 12, 2002 ~ ~ro ,,*r Honorable Magalie Roman Salas ro Secretary Federul Energy Regulatory Commission 888 First Street, NE Washington, DC 2O426 Re: Project No. 477 - Bull Run Hydroeleetric Project AppHcaton to ~¢nd and Surrendfr License Dear Secretary Salas: On October 24, 2002, Portland General Electric Company ("POE"), licensee for Project No. 477, the Bull Run Hydroelectric Project, and 22 other parties, including the State of Oregon and 9 state, federal, and local agencies, as well as 12 non-governmental organizations, signed an historic settlement agreement that provides for the orderly decommissioning and removal of Project No. 477. Accordingly, enclosed for filing with the Commission on behalfofPGE and the parties to the Settlement Agreement, are an original and eight copies of the filing package comprising PGE's application to amend and surrender the license for Project No. 477. This applicationconsists of the following documents: I. Application for Non-Capacity Amendment of License; 2. Application for Surrender of License; 3. Joint Explanatory Statement in Support of Decommissioning Settlement Agreement; 4. Settlement Agreement Concerning the Removal of the Bull Run HydroelecUic Project;including a) Exhibit A: Decommissioning Plan; b) Exhibit B: Authorized Representatives of the Parties; c) Appendix A: Application for Amendment
    [Show full text]
  • San Francisco Fire Department Apparatus Inventory
    San Francisco Fire Department Apparatus Inventory 1 Apparatus Inventory August 2009 San Francisco Fire Department 698 Second Street San Francisco, CA 94107 3 Chief of Department Joanne Hayes-White Manual Revision Project Deputy Chief Gary P. Massetani Assistant Deputy Chief Thomas A. Siragusa Assistant Chief James A. Barden Captain Jose L. Velo Project Manager, Apparatus Inventory Captain Winona Jones Collaborators Firefighter Dana Pompeo Firefighter Nancy Galvin Captain Jerry Keohane Editor Lieutenant Dawn Dewitt Published by: Division of Training 2310 Folsom St San Francisco, Ca 94110 Phone: (415) 970-2000 Front Cover: Box 5535, 1470 Valencia St. , 4th Alarm, March 17, 2008 File: Apparatus Inventory 2009 This manual is the sole property of the San Francisco Fire Department 4 Table of Contents Page # Introduction ......................................................................................................1 Engine..............................................................................................................3 Truck................................................................................................................7 Medic Unit......................................................................................................11 Chief Vehicle..................................................................................................19 Rescue Captain Vehicle.................................................................................21 CO2 Unit ........................................................................................................25
    [Show full text]
  • Mts Muv 2017-2018
    MTS MUV 2017-2018 Manned Underwater Vehicles 2017-2018 Global Industry Overview By: William Kohnen, President Hydrospace Group Inc. Rancho Cucamonga, CA 91730 USA Chair, Manned UW Vehicles Cmttee Marine Technology Society Date: May 17, 2018 15th Annual MUV Symposium Underwater Intervention 2018 www.mtsmuv.org MTS MUV 2017-18 Global Industry Overview Table of Contents ABSTRACT ...................................................................................................................................................... 3 GENERAL REVIEW.......................................................................................................................................... 4 Alucia M/V (WHOI)...................................................................................................................................... 15 Aquatica Submarines, Canada .................................................................................................................... 15 Bulgaria Academy of Sciences (BAS), Bulgaria ............................................................................................ 16 China National Deep Sea Center (NDSC), P.R. China .................................................................................. 17 China Ship Scientific Research Center (CSSRC), P.R. China ......................................................................... 18 China Deep Submergence Rescue Vehicle, P.R. China ............................................................................... 19 DEEPFLIGHT, USA .......................................................................................................................................
    [Show full text]
  • School Ski Prograld.Set the New Mexico State Aviauon Depart
    ,~~"'~>' I~'"'' ,~e>', ~'n· .f~.~' ~, .l'\"'I',~ !-~ ... , ",..,..-;" ... .,-.. • ..... ,if'!'!" '-11"1' ~ -. 111'-' "'., ~"; .... , 1"',' ," , ''-:'' ... .""".~ .. ~'.,..-" ", .- ~'. -!I" l'!" .. ' ',.'....~ .. '~: ..... -. r','""-,:";1'; T ... ," "',', tf!U.: l'I"!: -. T"- .-r'. "' .. - ",: "e", -I \ ,'. '. ,I' ., . '\.,1 " " '~~, " .,1', , ... ' I ,'. ~ . ',' . ,,' .,,1' . ,',' " .. ' , '~ '. .. '.,',' , " 'J ..'~, l '~' .. JScPERCOPY '" I' ,', The ) o ;J " ' VOLUME NO. 72 IN OUR 32ND YEAR RUIOO$.O,L;fNCOi.N.COUNTY, NEWMEXIC'O:Q83,45 . ," 1978 , '.' ,".," .. MONDAY,JANUARY 23, [< •• . ' , ~ '" f " esnow '0' " BY ~ALE DICKEY 't'res· would have overpoweredChantlcleer~scr~wanyhow ­ Editor 'cavse there's no rooster.alive as can compete with tires singing Chanticleer's muffled crow didn't ring out over the valley. on wet.bla·c;ktop at aspeedo.meter reading of 80, and no forward Friday morning - no Chanticleers with crows to be muffled by progress being made ~y s~me vehicle, not to mention the' the six Inch snow fall blanketing Ruidoso. disgruntled drIver of same. , Now that six' Inches of snow depends upon where you were. And the word gQt out that skIIng wasbooming. About midtown" and at the airpOrt, that's a reasonably close measurement - 'cause that's what the official measurer at the Early Friday morn an endless string ofcars- with skits In .. airport measured. '. .carriers, as well as sticking out of windows -were en route to . the ski area. With the lineup at the service stations, to have Up toward Alto Hill, the snow was deeper than'the four.. buckle chains Installed, lust about as long as the IIhes forming at the overshoes on a four-year-old reach toward his knees. various lifts at the ski area. , --- - ' Dachshunds were having problems keeping their nose above \ the fluffy blanket, though their owners had no trouble tracking And there' was" a change in the atmosphere In Ruidoso -:­ them.
    [Show full text]
  • Preparation Date 2013/04/20 Revision Date 2016/01/12
    WDR11-A, PENTEL CO., LTD., 4, 2014/10/29, 1/5 Safety Data Sheet (SDS) Preparation Date 2013/04/20 Revision Date 2016/01/12 Section 1 - CHEMICALS AND COMPANY IDENTIFICATION Chemical IdentifierWDR11-A Product Code WDR11A0001 Company Name PENTEL CO., LTD. Address 7-2,KOAMICHO,NIHONBASHI,CHUO-KU,TOKYO Company Contact QUALITY ASSURANCE DEPARTMENT I Phone Number 048-928-6668 Fax Number 048-928-9190 Mail Address [email protected] Emergency Phone 048-928-6668 Number Recommended Use ink and Restriction on Use LRN5/7,LRN5H,LRNT5,LR7/10,BLN15/23/25/75/ 105,BL17/27/30/57/77/107,BL60,BL80,BL110-A Section 2 - HAZARDS IDENTIFICATION GHS Classification Health Hazards Serious eye damage/eye irritation Category 2B Specific target organ toxicity (single exposure) Category 2(respiratory apparatus,heart,kidney,central nervous system Specific target organ toxicity (repeated exposure) Category 2(respiratory apparatus,heart,central nervous system) Environmental Hazard to the aquatic environment (acute hazar Hazards Category 2 Hazard to the aquatic environment (long-term hazard) Category 2 Other hazards than mentioned above are Not applicable or No data available. GHS Label Elements Symbols Signal Word Warning Hazard Statements H320 Causes eye irritation H371 May cause damage to respiratory apparatus,heart,kidney,central nervous system H373 May cause damage to respiratory apparatus,heart,central nervous system through prolonged or repeated exposure H411 Toxic to aquatic life with long lasting effec Precautionary Statements Prevention Do not get in eyes, on skin, or on clothing.(P262) Precautionary Statements WDR11-A, PENTEL CO., LTD., 4, 2014/10/29, 2/5 Response IF exposed or concerned: Call a POISON Precautionary CENTER/doctor/...(P308+P311) Statements IF IN EYES: Rinse cautiously with water for several minutes.
    [Show full text]
  • The Secretwar the Secretwar
    NEL(d THE SECRETWAR THE SECRETWAR CIA covert operations against Cuba 1959-62 By FabiSn Escalante Translated by Maxine Shaw Edited by Mirta Mufriz OCEAN PRESS ir X Contents X l'rcfac'e by Carlos Lechuga Cbaprcr 1 An ugly American 5 Cbaprcr 2 The Cover design by David SPratt Trujillo cons piracy t7 Cbapter 3 The plot 30 Copyright O 1995 Fabian Escalante Copyright @ 1995 Ocean Press Chaprcr 4 Operation 40 39 in a Chapter 5 Operation Pluto Atl rights reserved. No part of this publication may be reproduced, stored 60 form or by any means, electronic, retrieval system or transmitted in any Chaprcr 6 The empire strikes back: mechanical, photocopying, recording or otherwise, without the prior permission Operations Patty and Liborio 87 of the publisher. Chapter 7 Operation Mongoose 101 ISBN r-875284-86-9 Chaptur I The conspirators tt4 First printed 1995 Cbapter 9 Executive Action 129 Chapter 10 Special Printed in Australia operarions 136 Epilogue 149 Published by Ocean Press, Cbronology t5t GPO Box 1}79,Melbourne, Victoria 3001, Australia Glossary 193 Index 196 Distributed in tbe Ilnited Sates by the Tdman Company, 131 Spring Street, New York, NY 10012, USA Distributed in Briain and. Europe by Central Books, 99 \flallis Road, London E9 5LN, Britain Distributed in Australia by Astam Books, 57-61John Street, Leichhardt, NS\f 2040, Australia Distributed in Cuba and Latin America by Ocean Press, Apartado 686, C.P. 11300, Havana, Cuba Distributed in Southem AfricabY Phambili Agencies, SlJeppe Street, Johannesburg 2001, South Africa trw' About tbe autbor Division General Fabiin Escalante Font was born in the city o[ I fuvana, cuba, in 1940.
    [Show full text]